MODULATION sAPP, sAPPα AND BDNF LEVELS IN INDIVIDUALS DIAGNOSED WITH FXS AND ASD Russian patent published in 2018 - IPC G01N33/53 G01N33/68 A61K31/195 A61P25/28 

FIELD: medicine.

SUBSTANCE: group of inventions relates to the modulation of serum protein levels for the treatment of patients with fragile X chromosome syndrome (FXS) and autism spectrum disorders (ASD). Disclosed is a method of treating ASD or FXS in a patient, comprising steps of: contacting a first plasma sample from a patient diagnosed with ASD or FXS with reagents that selectively bind to brain-derived neurotrophic factor (BDNF), secreted amyloid precursor protein (sAPP), secreted amyloid alpha precursor protein (sAPPα); determining BDNF, sAPP and sAPPα levels in said plasma sample; administering acamprosate or a pharmaceutically acceptable salt thereof to a patient; binding a second plasma sample from said patient with reagents that selectively bind to BDNF, sAPP, sAPPα; determining if there is a change in the levels of BDNF, sAPP and sAPPα in the plasma of said patient; adjusting the amount of acamprosate or a pharmaceutically acceptable salt thereof administered to said patient in response to a change in the levels of BDNF, sAPP and sAPPα, determined in the plasma samples of said patient. Also disclosed is the use of a system for monitoring the treatment of ASD and FXS, a method of screening for a compound for the treatment of ASD and FXS, and a method for treating ASD or FXS in a patient, including administering acamprosate and monitoring the patient's peripheral blood.

EFFECT: group of inventions provides effective monitoring of the treatment of ASD and FXS.

16 cl, 2 dwg, 8 tbl